文献速递淋巴瘤

STAG2突变微调ALK阳性间变性大细胞淋巴瘤的ALK驱动致癌程序

STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.
PubMed 文献 · Blood · 2026-10-05

该研究通过对ALK阳性间变性大细胞淋巴瘤(ALK+ ALCL)患者肿瘤与正常组织配对全外显子测序,发现黏连蛋白复合物基因突变频率较高,其中STAG2变异占6/16且预测损害蛋白功能。利用NPM1::ALK驱动淋巴瘤发生的原始模型,证明STAG2缺陷加速致癌过程、增强ALK阳性细胞早期增殖,单细胞RNA测序揭示STAG2耗竭加速ALK+ ALCL主要标志的早期获得并减少致癌基因诱导的衰老特征。

要点

  • ALK+ ALCL中黏连蛋白复合物基因突变频率较高,STAG2变异占6/16且预测功能受损。
  • STAG2缺陷加速NPM1::ALK驱动淋巴瘤发生,增强ALK阳性细胞早期增殖。
  • STAG2耗竭加速ALK+ ALCL标志获得、减少衰老特征并增加细胞黏附迁移。

核心结论

  • STAG2缺失在ALK+ ALCL淋巴瘤发生最早阶段起关键作用,促进细胞对NPM1::ALK表达的耐受并增加恶性转化易感性,同时影响细胞黏附与迁移。

研究设计与样本

  • 对ALK+ ALCL患者肿瘤与匹配正常组织进行配对全外显子测序。
  • 使用NPM1::ALK驱动的原始淋巴瘤发生模型,该模型重现原代T淋巴细胞中ALK驱动转化的早期步骤。
  • 采用单细胞RNA测序分析STAG2耗竭后的转录程序变化。

主要发现

  • 与既往研究相比,鉴定出黏连蛋白复合物基因突变频率更高,主要为STAG2变异(6/16)且预测损害蛋白功能。
  • 免疫组化在额外患者肿瘤样本中证实STAG2缺失。
  • STAG2缺陷加速致癌过程,增强ALK阳性细胞早期增殖。
  • 单细胞RNA测序显示STAG2耗竭加速ALK+ ALCL主要标志的早期获得,同时减少致癌基因诱导的衰老特征。
  • 尽管ALK表达更高且细胞转化强,STAG2耗竭导致整体ALK+ ALCL转录程序减弱。

关键数值与推荐

  • STAG2变异占6/16,预测损害蛋白功能。
  • NPM1::ALK诱导后STAG2表达下降,提示转化过程中内在下调即使无基因组突变。
  • 在患者来源肿瘤和PDX模型中鉴定出STAG2-low/ALK-high细胞。
  • STAG2耗竭细胞显示细胞黏附与迁移增加,伴随YAP1组成性激活及黏附分子ALCAM和CD44上调,PD-L1也增加。

临床怎么用

  • STAG2缺失可能作为ALK+ ALCL早期淋巴瘤发生的标志,有助于理解转化机制。
  • STAG2-low/ALK-high细胞在患者肿瘤和PDX模型中的发现提示其临床相关性。
  • STAG2状态可能影响细胞黏附、迁移及免疫微环境,需进一步研究其治疗意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ALK-positive Anaplastic Large Cell Lymphoma (ALK+ ALCL) is a rare yet aggressive T-cell lymphoma, most often characterized by the NPM1::ALK fusion. Because few somatic variants have been identified in ALK+ ALCL, we conducted paired whole-exome sequencing of patient tumors with matched normal tissue. Compared with previous studies, we identified a higher frequency of mutations in cohesin complex genes, mostly STAG2 variants (6/16) predicted to impair protein function. Immunohistochemistry confirmed loss of STAG2 in additional patient tumor samples. Using an original model of NPM1::ALK-driven lymphomagenesis that recapitulates early steps of ALK-driven transformation initiated in primary T lymphocytes, we demonstrated that STAG2 defect accelerates oncogenesis, enhancing early cell proliferation of ALK-positive cells. Single-cell RNA-seq revealed that STAG2 depletion accelerates the early acquisition of the major ALK+ ALCL hallmarks and concomitantly reduces the oncogene-induced senescence signature. Despite higher ALK expression and robust cell transformation, STAG2 depletion resulted in the attenuation of the global ALK+ ALCL transcriptional program. Importantly, STAG2 expression was found decreased upon NPM1::ALK induction, indicating intrinsic downregulation during transformation even without genomic mutations. We also successfully identified STAG2-low/ALK-high cells in both patient-derived tumors and PDX models. Functionally, STAG2-depleted cells exhibit increased cell adhesion and migration, alongside constitutive YAP1 activation and upregulation of adhesion molecule such as ALCAM and CD44 but also increased PD-L1. Overall, our findings reveal that STAG2 loss plays a key role during the earliest stages of ALK+ ALCL lymphomagenesis by promoting cell tolerance to NPM1::ALK expression and increasing permissiveness to malignant transformation while also impacting cell adhesion, migration.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Borry R, Vilcot F, Tesson B, et al. STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma. Blood. 2026. PMID: 42832421. doi:10.1182/blood.2025032902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。